Annually, Megace ES
has generated combined sales of USD17.
Some people may experience side effects associated with Megace ES
that include impotence, passing gas, rash, high blood pressure, fever, decreased libido, insomnia, upset stomach, and elevated blood sugar.
Virtually immediately, the Megace ES
therapy was associated with more rapid weight gain compared to Megace and the effect was sustained for the full 12 week duration of the trial.
The Megace ES
package insert notes the following potential adverse effects: diarrhea, cardiomyopathy, palpitation, hepatomegaly, leukopenia, edema, paresthesia, confusion, convulsion, depression, neuropathy, hypesthesia and abnormal thinking, thrombophlebitis, pulmonary embolism, and glucose intolerance.
The EPS forecast for 2006 is based on Megace ES
sales reaching $70m.
In June, the company announced that it filed a Paragraph IV for the ANDA of Megace ES
by Strativa Pharmaceuticals, a division of Par Pharmaceutical Inc.